Concepedia

Dorothée Sémiond

DS

20

Publications

1.4K

Citations

18

H-Index

1998

Active since

Affiliations

Sanofi (France)(Current)

Sanofi (United States)

Sanofi (Germany)

AVEO Oncology (United States)

Institut Jules Bordet

Dorothée Sémiond is an author at Sanofi (France) specializing in medicine, pharmacotherapy, and pharmacology.

Top concepts

Publications per year

1998–2023

20

Publications

20

Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors

Alain C. Mita, Louis Denis, Eric K. Rowinsky et al. · Clinical Cancer Research · 2009 · 328 citations

Preclinical Antitumor Activity of Cabazitaxel, a Semisynthetic Taxane Active in Taxane-Resistant Tumors

Patricia Vrignaud, Dorothée Sémiond, Pascale Lejeune et al. · Clinical Cancer Research · 2013 · 221 citations

Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P‐glycoprotein at the blood–brain barrier in mice and rats

Salvatore Cisternino, Fanchon Bourasset, Yves Archimbaud et al. · British Journal of Pharmacology · 2003 · 112 citations · Full text

A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma

Joseph Mıkhael, Paul G. Richardson, Saad Z. Usmani et al. · Blood · 2019 · 88 citations · Full text

A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer

D. Rea, J. W. R. Nortier, W.W. ten Bokkel Huinink et al. · Annals of Oncology · 2005 · 79 citations

, , +7

Rows per page

1–5 of 20